{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:44:19Z","timestamp":1793371459993,"version":"4.5.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1156072"],"award-info":[{"award-number":["1156072"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2017131"],"award-info":[{"award-number":["2017131"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT \\u2013 195881"],"award-info":[{"award-number":["PJT \\u2013 195881"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015070","name":"Department of Psychiatry, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025077","name":"Faculty of Medicine, University of Ottawa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euroneuro.2025.09.011","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:28:09Z","timestamp":1762554489000},"page":"41-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5786-5203","authenticated-orcid":false,"given":"Mikkel","family":"H\u00f8jlund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helin Y.","family":"Kafali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beg\u00fcm","family":"K\u0131rm\u0131z\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fusar-Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Sab\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2057-4071","authenticated-orcid":false,"given":"Jess","family":"Fiedorowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Zein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5554-6946","authenticated-orcid":false,"given":"Michael","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad I.","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7973-5199","authenticated-orcid":false,"given":"Ruby","family":"Rubaiyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Corace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7316-5370","authenticated-orcid":false,"given":"Stanley","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3117-2350","authenticated-orcid":false,"given":"Simon","family":"Hatcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kaluzienski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi N.","family":"Yatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-8321","authenticated-orcid":false,"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin J.","family":"Gosling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carhart-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tanuseputro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Myran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6873-5105","authenticated-orcid":false,"given":"Nicholas","family":"Fabiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Moher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah M.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart G.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2716-047X","authenticated-orcid":false,"given":"Tracy","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2032-1181","authenticated-orcid":false,"given":"Michele De","family":"Prisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Radua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim S.","family":"Ladha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areti A.","family":"Veroniki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-7233","authenticated-orcid":false,"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2025.09.011_bib0001","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","article-title":"Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type ii major depressive episodes: a nonrandomized open-label trial","volume":"81","author":"Aaronson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0002","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.13249","article-title":"Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies","volume":"143","author":"Andersen","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0003","unstructured":"Australian Living Evidence Collaboration, 2022. The living guidelines handbook: guidance for the production and publication of living clinical practice guidelines 1.0."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.49026","article-title":"Psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: a randomized clinical trial","volume":"7","author":"Back","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2019.109735","article-title":"Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: a systematic review and meta-analysis","volume":"96","author":"Bahji","year":"2020","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0006","first-page":"1","article-title":"Efficacy and safety of four psychedelic-assisted therapies for adults with symptoms of depression, anxiety, and posttraumatic stress disorder: a systematic review and meta-analysis","author":"Bahji","year":"2023","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0007","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0008","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0009","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/02791072.2008.10400637","article-title":"MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder","volume":"40","author":"Bouso","year":"2008","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00005053-197002000-00003","article-title":"Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study","volume":"150","author":"Bowen","year":"1970","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0011","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1177\/02698811221116926","article-title":"Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review","volume":"36","author":"Breeksema","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0012","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jpsychires.2022.03.008","article-title":"MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD","volume":"149","author":"Brewerton","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0013","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.mp.4001852","article-title":"Treatment-resistant anxiety disorders","volume":"11","author":"Bystritsky","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2023.05.008","article-title":"Psychedelics in the treatment of eating disorders: rationale and potential mechanisms","volume":"75","author":"Calder","year":"2023","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0015","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0016","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0017","unstructured":"Cochrane Statistical Methods Group, 2022. Random-effects meta-analysis methods for intervention reviews [WWW Document]. URL https:\/\/methods.cochrane.org\/methods-cochrane\/random-effects-meta-analysis-methods-intervention-reviews (accessed 6.10.24)."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0018","series-title":"Statistical Power Analysis For the Behavioral Science","author":"Cohen","year":"1988"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0019","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/wps.21056","article-title":"The future of psychopharmacology: a critical appraisal of ongoing phase 2\/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents","volume":"22","author":"Correll","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0020","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","article-title":"Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study","volume":"235","author":"Danforth","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0021","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0022","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1192\/bjp.116.533.443","article-title":"A controlled study of LSD treatment in alcoholism and neurosis","volume":"116","author":"Denson","year":"1970","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0023","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","article-title":"Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews","volume":"11","author":"Dos Santos","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0024","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/JCP.0000000000001428","article-title":"Ayahuasca improves self-perception of speech performance in subjects with social anxiety disorder: a pilot, proof-of-concept, randomized, placebo-controlled trial","volume":"41","author":"Dos Santos","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0025","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2007.06111868","article-title":"Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report","volume":"165","author":"Fava","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0026","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.drugalcdep.2016.08.625","article-title":"Remission from substance use disorders: a systematic review and meta-analysis","volume":"168","author":"Fleury","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0027","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3389\/fpsyt.2019.00943","article-title":"Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials","volume":"10","author":"Fuentes","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0028","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00213-020-05719-1","article-title":"Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants","volume":"238","author":"Galv\u00e3o-Coelho","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0029","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112749","article-title":"The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis","volume":"284","author":"Goldberg","year":"2020","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0031","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0032","first-page":"1","article-title":"metaConvert: an automatic suite for estimation of 11 different effect size measures and flexible conversion across them","author":"Gosling","year":"2025","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0033","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0034","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115531","article-title":"Psilocybin-assisted therapy for depression: a systematic review and meta-analysis","volume":"329","author":"Haikazian","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0036","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0037","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1176\/ajp.125.10.1352","article-title":"A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics","volume":"125","author":"Hollister","year":"1969","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0038","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0039","article-title":"Pharmacological-assisted Psychotherapy for Post-Traumatic Stress Disorder: a systematic review and meta-analysis","volume":"12","author":"Hoskins","year":"2021","journal-title":"Eur. J. Psychotraumatol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0040","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/02698811231180276","article-title":"Risk of bias in randomized clinical trials on psychedelic medicine: a systematic review","volume":"37","author":"Hovmand","year":"2023","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0041","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","article-title":"Treatment resistance in psychiatry: state of the art and new directions","volume":"27","author":"Howes","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0042","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13643-023-02396-x","article-title":"Methods and guidance on conducting, reporting, publishing, and appraising living systematic reviews: a scoping review","volume":"12","author":"Iannizzi","year":"2023","journal-title":"Syst. Rev."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0043","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0269881120965915","article-title":"A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: a systematic review and meta-analysis","volume":"35","author":"Illingworth","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0044","article-title":"Psilocybin as a treatment for psychiatric illness: a meta-analysis","volume":"14","author":"Irizarry","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0045","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1002\/sim.7411","article-title":"The Hartung-Knapp modification for random-effects meta-analysis: a useful refinement but are there any residual concerns?","volume":"36","author":"Jackson","year":"2017","journal-title":"Stat. Med."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0046","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1176\/ajp.126.4.481","article-title":"LSD in the treatment of alcoholism","volume":"126","author":"Johnson","year":"1969","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0047","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1017\/S0033291716002774","article-title":"The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis","volume":"47","author":"Kamenov","year":"2017","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0048","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/00048674221083868","article-title":"A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders","volume":"57","author":"Kisely","year":"2023","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0049","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.beth.2020.04.015","article-title":"The effect of concurrent depression on PTSD outcomes in trauma-focused psychotherapy: a meta-analysis of randomized controlled trials","volume":"52","author":"Kline","year":"2021","journal-title":"Behav. Ther."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0050","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jad.2022.09.168","article-title":"Psychedelic therapy for depressive symptoms: a systematic review and meta-analysis","volume":"322","author":"Ko","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0051","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0052","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/02698811211044688","article-title":"Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: a systematic review and meta-analysis","volume":"36","author":"Leger","year":"2022","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0053","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jad.2021.09.041","article-title":"Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis","volume":"296","author":"Li","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0054","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1176\/ajp.126.1.59","article-title":"A clinical study of LSD treatment in alcoholism","volume":"126","author":"Ludwig","year":"1969","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/02791072.2020.1769878","article-title":"A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy","volume":"52","author":"Luoma","year":"2020","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0056","doi-asserted-by":"crossref","DOI":"10.1111\/add.70152","article-title":"Psilocybin in alcohol use disorder and comorbid depressive symptoms: results from a feasibility randomized clinical trial","author":"Luquiens","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0057","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.euroneuro.2023.02.002","article-title":"Premise, promise and challenges of MDMA assisted therapy for PTSD","volume":"70","author":"Madero","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0058","doi-asserted-by":"crossref","first-page":"e725","DOI":"10.1016\/j.jpainsymman.2022.01.024","article-title":"The therapeutic potential of psychedelic-assisted therapies for symptom control in patients diagnosed with serious illness: a systematic review","volume":"63","author":"Maia","year":"2022","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0059","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078084","article-title":"Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis","volume":"385","author":"Metaxa","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0060","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0061","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0062","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0063","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of {\u00b1}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2011","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0064","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2025.0044","article-title":"Safety and efficacy of repeated low-dose LSD for ADHD treatment in adults: a randomized clinical trial","author":"Mueller","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100725","article-title":"Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: a randomized trial","author":"M\u00fcller","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0067","unstructured":"National Institute on Drug Abuse, 2023. Psychedelic and dissociative drugs [WWW Document]. URL https:\/\/nida.nih.gov\/research-topics\/psychedelic-dissociative-drugs (accessed 10.3.24)."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0068","series-title":"Randomized, double-blind, active placebo-controlled pilot study of MDMA-assisted psychotherapy in people with chronic PTSD [WWW Document]","year":"2008"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0069","series-title":"Randomized, double-blind, controlled of MDMA-assisted psychotherapy in 12 subjects with PTSD [WWW Document]","year":"2022"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0070","series-title":"Treatment-Resistant Social Anxiety Disorder, in: Management of Treatment-Resistant Major Psychiatric Disorders","first-page":"125","year":"2012"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109356","article-title":"The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD","volume":"233","author":"Nicholas","year":"2022","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0072","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0269881112464827","article-title":"A randomized, controlled pilot study of MDMA (\u00b1 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD)","volume":"27","author":"Oehen","year":"2013","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0073","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/0269881118806297","article-title":"3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial","volume":"32","author":"Ot\u2019alora","year":"2018","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0074","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0075","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jama.1970.03170240060010","article-title":"The experimental use of psychedelic (LSD) psychotherapy","volume":"212","author":"Pahnke","year":"1970","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0076","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0077","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.euroneuro.2023.07.011","article-title":"Psilocybin-assisted therapy for depression: a systematic review and dose-response meta-analysis of human studies","volume":"76","author":"Perez","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0078","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0079","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-024-01622-3","article-title":"MDMA therapy for PTSD rejected by FDA panel","author":"Reardon","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103149","article-title":"Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial","volume":"82","author":"Rieser","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0081","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0082","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/0269881120919957","article-title":"Efficacy of psychedelic treatments on depressive symptoms: a meta-analysis","volume":"34","author":"Romeo","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0083","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/09540261.2018.1482261","article-title":"Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress","volume":"30","author":"Ross","year":"2018","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0084","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0085","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study","volume":"28","author":"Savage","year":"1973","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0086","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0087","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3389\/fphar.2018.00733","article-title":"Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development","volume":"9","author":"Schenberg","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0088","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/02698811211069100","article-title":"Adverse effects of psychedelics: from anecdotes and misinformation to systematic science","volume":"36","author":"Schlag","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0089","series-title":"Meta-Analysis With R, Use R!","author":"Schwarzer","year":"2015"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0090","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/03007995.2023.2296968","article-title":"The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis","volume":"40","author":"Sicignano","year":"2024","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0091","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/COC.0000000000000998","article-title":"The impact of psychedelic drugs on anxiety and depression in advanced cancer or other life-threatening disease: a systematic review with meta-analysis","volume":"46","author":"Sicignano","year":"2023","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0092","doi-asserted-by":"crossref","first-page":"469","DOI":"10.15288\/qjsa.1966.27.469","article-title":"A controlled study of lysergide in the treatment of alcoholism. I. The effects on drinking behavior","volume":"27","author":"Smart","year":"1966","journal-title":"Q. J. Stud. Alcohol"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0093","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcph.1995","article-title":"MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: a systematic review with meta-analysis","volume":"62","author":"Smith","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0094","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-072348","article-title":"Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies","volume":"382","author":"Solmi","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0095","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40501-017-0130-0","article-title":"Management of treatment-resistant posttraumatic stress disorder","volume":"4","author":"Starke","year":"2017","journal-title":"Curr. Treat. Options Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0096","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0097","article-title":"The efficacy of MDMA (3,4-Methylenedioxymethamphetamine) for post-traumatic stress disorder in humans: a systematic review and meta-analysis","volume":"13","author":"Tedesco","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0098","doi-asserted-by":"crossref","first-page":"932","DOI":"10.15288\/qjsa.1970.31.932","article-title":"Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation","volume":"31","author":"Tomsovic","year":"1970","journal-title":"Q. J. Stud. Alcohol"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0099","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295926","article-title":"Effects of MDMA-assisted therapy for PTSD on self-experience","volume":"19","author":"van der Kolk","year":"2024","journal-title":"PloS One"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0100","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1134454","article-title":"Therapeutic effect of psilocybin in addiction: a systematic review","volume":"14","author":"van der Meer","year":"2023","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0101","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/biomedicines8090331","article-title":"Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases-a systematic review and meta-analysis of clinical trials","volume":"8","author":"Vargas","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0102","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0103","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"Von Rotz","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0104","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75706-1","article-title":"MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study","volume":"10","author":"Wolfson","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0105","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/jcm11040938","article-title":"Trajectory of antidepressant effects after single- or two-dose administration of psilocybin: a systematic review and multivariate meta-analysis","volume":"11","author":"Yu","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0106","doi-asserted-by":"crossref","first-page":"958","DOI":"10.30773\/pi.2021.0209","article-title":"Psilocybin for end-of-life anxiety symptoms: a systematic review and meta-analysis","volume":"18","author":"Yu","year":"2021","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0107","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euroneuro.2023.09.007","article-title":"Methodological concerns in psychedelic research: the issues of nonequivalent psychological support and generalizability","volume":"78","author":"Zeifman","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.09.011_bib0108","article-title":"Decreases in suicidality following psychedelic therapy: a meta-analysis of individual patient data across clinical trials","volume":"83","author":"Zeifman","year":"2022","journal-title":"J. Clin. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2500762X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2500762X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:25:06Z","timestamp":1773314706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X2500762X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":108,"alternative-id":["S0924977X2500762X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.09.011","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}